473 results about "Treating tuberculosis" patented technology

A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.

The present invention relates to a medicine, in particular to a medicinal composition which is used for treating tuberculosis, and a preparation method thereof. The medicinal composition is prepared from raw materials of the following weight percent: 50 grams of Chinese yam, 30 grams of radix rehmanniae, 10 grams of radix asparagi, 10 grams of dwarf lilyturf root, 30 grams of rhizoma polygonati, 30 grams of prepared radix-polygoni multiflori, 20 grams of radix astragali, 10 grams of tuckahoe, 8 grams of Astraolylis lancea formalyrata, 10 grams of fritillary bulb, 10 grams of Beishashen, 20 grams of codonopsis pilosula, 20 grams of cornel, 20 grams of fructus schizandrae, 20 grams of radix salviae miltiorrhizae, 10 grams of galli stomachichum corium, 20 grams of hawthorn, 20 grams of ass-skin glue, 15 grams of fructus trichosanthis, 15 grams of bletilla, 20 grams of angelica, 20 grams of root of herbaceous peony, 8 grams of licorice, 10 grams of lily, 10 grams of rhizoma anemarrhenae, 10 grams of radix bupleuri, 8 grams of radix scutellariae, 10 grams of dried old orange, and 150 grams of refined honey. The medicinal composition has the advantages of scientific, reasonable and precise formula, and can be used for nourishing yin, lung, spleen, kidney and stomach. And the medicinal composition can be used for benefiting qi, nourishing yin, moistening lung, stopping cough, invigorating kidney, protecting spleen, and treating various diseases.

The invention discloses a tuberculosis gene vaccine based on T cell epitopes, wherein a full-length gene, embedded with four T cell epitope polypeptide genes which come from mycobacterium tuberculosis antigen, of mycobacterium tuberculosis heat shock protein is inserted into a vector. The invention also discloses a method for preparing the vaccine, which comprises the following steps: four T cell epitope genes, namely EAST-6189-228, Ag85A369-405, CFP10162-207 and Ag85B420-459 which come from the mycobacterium tuberculosis antigen are inserted into an HSP65 full-length gene. The invention also discloses application of an ECANS tuberculosis gene vaccine. Through the intramuscular injection of the gene vaccine into an immune mouse, the experiment proves that the vaccine can induce a specific antibody which aims at a plurality of tuberculosis antigens to response, can induce stronger tuberculosis specific killing response, can induce Th1 immune response at the same time, secrete high-level IFN gamma, and is a good vaccine for preventing and treating tuberculosis.

Methods and compositions for the treatment of mycobacteria infections, particularly antibiotic resistant strains. Of particular use in treating tuberculosis infections, including dormant or difficult to treat forms.

The invention discloses streptomyces atratus and application of cyclic peptide compounds with the same to preparing mycobacterium tuberculosis resistant medicines. A structural formula of the cyclic peptide compounds is shown. A preservation number of the streptomyces atratus SCSIO Zh16 is CGMCC No.12198. The streptomyces atratus and the application have the advantages that the six cyclic peptide compounds are obtained from fermentation cultivation substances of the streptomyces atratus SCSIO Zh16 by means of separation, the cyclic peptide compound 6 is high in mycobacterium tuberculosis resistant activity, obvious effects of inhibiting mycobacterium tuberculosis can be realized by the cyclic peptide compound, accordingly, the cyclic peptide compounds can be used for preparing anti-tuberculosis medicines and can be used for treating tuberculosis, alternative compounds can be provided for developing novel anti-tuberculosis medicines, and the streptomyces atratus and the application have important significance on developing marine medicinal materials in China.

The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible Mycobacterium tuberculosis strains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein. The derivatives were synthesized using a di-nitro-thiophene or 4-Chloro-5-Nitro-thiazole scaffold and R groups connected via a peptide bond (NHCO) to cyclic compounds such as benzene, thiophene or furans. Many of these compounds have broad spectrum activity against Gram positive bacteria including Staphylococcus aureus (MRSA) and Staphylococcus epidermidis. Several of these lead compounds were not toxic for mice at 200 mg/Kg doses administered over a period of three days.

The invention discloses a Chinese medicinal pill preparation for treating tuberculosis pleuritis, peritonitis, empyema and broncho-pleural fistula, which is prepared from 26 kinds of Chinese medicinal herbs including notoginseng, lily bulb, Sichuan fritillary bulb, lepidium seed, selfheal and weeping forsythia through steps of disintegrating, sieving, mixing homogenously, making water pills, and drying at low temperature.

Disclosed is a Chinese medicament for treating pulmonary tuberculosis which compirses Chinese angelica root 12g, dried rehmannia root 20g, coptis root 4g, baikal skullcap root 12g, phellodendron bark 15g, astragalus root 50g, root of balloonflower 15g, Sichuan fritillary bulb 6g, beach silvertop root 15g, roor of sessile stemona 27g, pericarpium trichosanthis 15g, mulberry bark 15g, batryticated silkworm 12g, smoked plum 15g, light wheat 15g, oyster 20g, poria cocos wolf 15g, Chinese yam 20g, cardamom seed 6g, root of pilose asiabell 20g, ophiopogon root 15g, schisandra fruit 6g. The Chinese medicament has simplified recipe and low price.

The Chinese medicine for treating tuberculosis is one kind of medicine powder prepared with astragalus root, curcuma root, Zhejiang fritillary bulb, notoginseng, bletilla tuber and other 20 kinds of Chinese medicinal materials. The Chinese medicine of the present invention treats tuberculosis with four main symptoms of cough, hemoptysis, afternoon fever and night sweat caused by lung-Yin deficiency and qi and blood deficiency systematically. The Chinese medicine of the present invention has short treating period, fast acting, no recurrence and no toxic side effect.

The invention discloses an application of single nucleotide polymorphism rs3888188 to detection of tuberculosis susceptibility. The SNP (Single Nucleotide Polymorphism) is the rs3888188 and is positioned in a human IFITM3 (interferon induced transmembrane protein) gene core promoter region (namely the upstream 103bp of a transcription initiation site/the upstream 204bp of a translation initiation site ATG), the rs3888188G is a risk factor of tuberculosis susceptibility, and the polymorphism of the rs3888188 is highly related with tuberculosis. When the genotype of the site is GG, the tuberculosis susceptibility or tuberculosis causing risk of an individual to be detected is increased. The application is of significant meaning and value in the aspects of diagnosing and treating the tuberculosis to reasonably prevent the tuberculosis.

The present invention discloses a non-cell corynebacterium parvum preparation (NCP) and its application in preparation of medicine for curing tuberculosis, in which the described NCP is a non-cell preparation prepared by breaking corynebacterium parvum, its grain size is less than 100 nm, and its heat source is less than 160 Eu/ml, protein content is 10-40% (g/g), nucleic acid content is 3-25% (g/g), the rest is polysaccharide. The tests show that it can obtain good therapeutic effect.

The invention relates to a medicament for treating tuberculosis, which is prepared from Chinese medicinal herbs. The medicament is characterized by consisting of the following raw material medicaments: 20 to 40g of toad, 270 to 320g of buttercup root, 100 to 150g of delavay parnassia herb, 45 to 70g of pariphyllin, 45 to 70g of American maidenhair fern, 150 to 220g of carapax amydae and 80 to 120g of metaplexis japonica. The whole formula has the advantages of exquisite compatibility and to-the-point pathogenesis, and fully reflects the therapeutic principles of clearing heat and detoxicating, activating meridians and collaterals, dispersing swelling and dissipating stagnation, nourishing yin and benefiting vitality.

The invention discloses a traditional Chinese medicine combination for treating tuberculosis and belongs to the field of traditional Chinese medicines. According to the traditional Chinese medicine combination, fragrant solomonseal rhizome, lily, common bletilla pseudobulb, lalang grass rhizome, agrimonia pilosa ledeb, houttuynia cordata, white mulberry root-bark, panax notoginseng powder, stemona, turtle shell, licorice and tree peony bark are adopted to be combined, interact and complement and benefit each other. The traditional Chinese medicine combination has the effects of nourishing yin and moistening the lung, relieving a cough and eliminating phlegm. The traditional Chinese medicine combination is low in medicine cost and free of any side effect, the therapeutic effect is remarkable, the total effective rate in one course of treatment is 95%, and the total effective rate in two courses of treatment is 97.5%.

A natural pharmaceutical preparation for treating hypoproteinemia, includes at least one member selected from the group consisting of a drug of increasing human serum albium, a drug of improving and enhance immunity, a drug of treating hepatitis B, a drug of treating Hepatitis C, a drug of treating acquired immune deficiency syndrome (AIDS), a drug of treating Tuberculosis, a drug of treat Fibrosis, a drug of treating hydrothorax, a drug of easing pain, a drug of stopping diarrhea, a drug of arresting coughing, a drug of reducing inflammation, and a drug of increasing urine.

The invention relates to a traditional Chinese medicine composition for treating tuberculosis, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw material medicine: hoantchy root, rhizome polygonati, lily, dwarf lilyturf turber, radix stemonae, bletilla, peach kernel, salvia miltiorrhiza, donkey-hide gelatin, wild buckwheat root, bulbus fritilariae, trichosanthes bark, and radix glehniae. The medicine is generally suitable for tuberculosis patients, particularly suitable for patients suffering from combined chronic diseases such as tubercular meningitis, diabetes, chronic liver disease, chronic renal disease, and the like, fever, night sweat, and physical weakness.

The present invention provides aryl- or heteroaryl-diketo acid compounds effective to inhibit an activity of a Mycobacterial malate synthase enzyme or to inhibit a malate synthase activity in other bacteria having the enzyme. The compounds may be phenyl-naphthyl-, or thienyl-substituted diketo acids and carboxylate derivatives thereof. Also provided are methods of treating tuberculosis or other pathophysiological conditions associated with a malate synthase enzyme with the inhibitory compounds and methods of in silico design of the inhibitory compounds. In addition, the present invention provides the inhibitory compounds designed by this method. Furthermore, three-dimensional X-ray crystal structures of the Mycobacterial malate synthase complexed with the inhibitory compounds are provided. Further still a method for stabilizing an aromatic or heteroaromatic diketo acid or its prodrug or close analog in solution by derivatizing at least the ortho position on the aromatic ring is provided.

The invention relates to a mycobacterium tuberculosis specific fusion protein vaccine AB and preparation and application thereof. The fusion protein vaccine AB is formed by sequentially connecting Ag85A protein epitope and Ag85B protein epitope; and the amino acid sequence of the protein vaccine AB is shown by the sequence 3 in a sequence table. The AB/pET-30a recombinant plasmid is established from the Ag85A protein epitope and Ag85B protein epitope by the genetic engineering technology and then transferred into escherichia coli, and the expressed fusion protein is formed by sequentially connecting the epitopes of the proteins A and B. The mycobacterium tuberculosis specific fusion protein vaccine AB provided by the invention can obviously enhance the mouse specific cellular immune function and is mainly used for irritating the Th1 type immune reaction; and a mouse tuberculosis treating model can remarkably reduce the bacterial population of the organs, and can be used for preparing a medicine or vaccine for preventing or treating tuberculosis.

The invention relates to a Chinese medicament for treating tuberculosis, which has significant efficacy and no drug resistance. The invention adopts a technical scheme that the Chinese medicament for treating tuberculosis is characterized in that the Chinese medicament comprises the following raw material components in portion by weight: 10 to 20 portions of bulbus fritillariae cirrhosae, 15 to 25 portions of loquat leaves, 10 to 20 portions of radix stemonae, 10 to 20 portions of aster, 15 to 25 portions of coltsfoot, 10 to 20 portions of lilies, 10 to 20 portions of almonds, 10 to 20 portions of tangerine peel, 15 to 25 portions of Chinese wolfberry fruits, 25 to 35 portions of astragalus roots, 10 to 20 portions of white ginseng, 15 to 25 portions of glossy ganoderma, 15 to 25 portions of oysters, 15 to 25 portions of prunella vulgaris, 10 to 20 portions of angelica dahurica, 10 to 20 portions of green tangerine peel, 10 to 20 portions of corydalis tuber, 5 to 15 portions of fructus toosendan, 25 to 35 portions of bugloss, 10 to 20 portions of heartleaf houttuynia herb, 15 to 25 portions of bittersweet herb, 10 to 20 portions of gardenia, 10 to 20 portions of Baikal skullcap roots, 5 to 15 portions of licorice, 5 to 15 portions of cyrtomium rhizome, 15 to 25 portions of pangolin, 10 to 20 portions of Jiaosanxian, 15 to 25 portions of endothelium corneum gigeriae galli.

The Miao medicine for treating tuberculosis and rheumatic heart disease is prepared with the effective components of six kinds of Chinese medicinal materials including peach kernel, almond, croton, pepper, edible fungus and ginger in certain weight proportion and egg white. The preparation process includes soaking edible fungus, washing and cutting; collecting egg white; grinding the other five kinds of Chinese medicinal materials into fine powder; mixing all the ingredients via stirring to form paste as the medicine. The Miao medicine is painted on while cloth and coated to sole. The Miao medicine has unique recipe and usage, and high curative effect.

Disclosed is a pharmaceutical composition for treating tuberculosis which is prepared from the following Chinese medicinal herbs (by weight ratio): Radix Ranunculi Ternati 1-3 weight parts, toad venoms 1-3 weight parts, rhubarb horsetails 1-3 weight parts, fritillary 1-3 weight parts, selfheal 1-3 weight parts, asparagus root 1-3 weight parts. The invention also discloses the process for preparing the pharmaceutical composition.

This disclosure provides a method of treating a subject infected with a mycobacteria of the M. tuberculosis complex or infected with an atypical mycobacterium. Aspects of the method include administering to a subject in need thereof a therapeutically effective amount of an enantiomerically pure (R)-chloroquine agent. The (R)-chloroquine agent may be an analog or derivate of chloroquine having a particular stereochemistry at the position located alpha to the amino-quinoline core of the chloroquine agent. Also provided are methods of inhibiting mycobacteria of the M. tuberculosis complex or other atypical mycobacteria in a cell. Kits and pharmaceutical compositions for practicing the subject methods are also provided.

A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.

The traditional Chinese medicine for treating phthisis is prepared from active constituents and auxiliary materials and is characterized in that the active constituents and weight ratio are as follows: 130-200g of lily, 130-200g of stemona root, 130-200g of bletilla tuber, 130-200g of rhizoma imperatae, 130-200g of versioolor swallowwort root, 130-200g of Japanese ampelopsis, 130-200g of ophiopogon root, 130-200g of rhizoma anemarrhenae, 130-200g of fritillaria, 130-200g of baikal skullcap root, 130-200g of solomonseal, 130-200g of astragalus root, 2-4 parts of otter livers, and 4-6 parts of red-spotted lizards. The medicine has the effects of nourishing yin, reinforcing insufficiency, reducing fever, relieving coughs, promoting the production of the body fluid, tonifying the kidney, astringing stop bleeding, treating tuberculosis, destroying parasites, regenerating the tissue, assuaging pain and the like, and is suitable for the treatment of phthisis.